FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

スポンサーサイト 

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。
[ --/--/-- --:-- ] スポンサー広告 | トラックバック(-) | コメント(-)

【プレスリリースメモ】 RNAi関係 (2013.2.2)  

<Alnylam Pharmaceuticals>
Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer(2013.1.30)
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results(2013.1.31)

<Mesoblast>(Angioblast Systemsを買収)
MESOBLAST RECEIVES FDA CLEARANCE FOR PHASE 2 CLINICAL TRIAL OF MESENCHYMAL PRECURSOR CELLS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS(2013.1.30)

<Antisense Therapeutics>
FDA Approval of Kynamro(2013.1.30

<Arrowhead Research>
Arrowhead to Present at Upcoming Scientific Conferences(2013.2.1)

<Cerulean Pharma>
Cerulean Pharma to Present Avastin®-CRLX101 Synergy Data at the 15th International Symposium on Anti-angiogenic Therapy(2013.1.29)
Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer(2013.1.31)

<CytRx Corporation>
CytRx Announces Positive Results from Animal Trial with Combination Aldoxorubicin and Doxorubicin Therapy(2013.1.28)
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer(2013.1.31)

<Generex Biotechnology>
Generex Announces Details of Investor Conference Call(2013.1.29)
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies(2013.1.30)
Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine(2013.1.31)

<Gene Signal>
Eric Viaud, CEO, interviewed on Pharma TV(2013.1.31)

<Isis Pharmaceuticals>
Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia(2013.1.29)
Isis Pharmaceuticals To Provide Update On FDA Approval Of KYNAMRO™ (mipomersen)(2013.1.29)


<Mirna Therapeutics>
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors(2013.1.30)

<OPKO Health>
OPKO Closes Offering of $175 Million of 3.00% Convertible Senior Notes Due 2033(2013.1.31)

<Pharmaxis>
Pharmaxis Receives Negative Recommendation from PADAC(2013.1.31)
Pharmaxis Announces US$40 million Financing Agreement with NovaQuest(2013.1.31)

<Prosensa>
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio(2013.1.29)

<Regulus Therapeutics>
Regulus Appoints Mark G. Foletta to its Board of Directors(2013.1.31)

<Rosetta Genomics>
Rosetta Genomics to be Featured on The Balancing Act® Airing on Lifetime Television Network(2013.1.30)

<RXi Pharmaceuticals>
RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI‑109 Program(2013.1.30)

<Sarepta Therapeutics>
Statement From Sarepta Therapeutics on Stock Volatility(2013.1.30)

<Tekmira Pharmaceuticals>
Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery(2013.1.31)
【関連論文】 First-in-Man Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement.

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013(2013.1.31)
Valeant Completes Acquisition Of Natur Produkt In Russia(2013.2.1)

<Vical>
Vical Announces News Release and Conference Call Schedule for 2012 Financial Results (2013.1.30)

<アンジェスMG>
行使価額修正条項付新株予約権の大量行使に関するお知らせ(2013.1.29)
行使価額修正条項付新株予約権の月間行使状況に関するお知らせ(2013.2.1)


スポンサーサイト
[ 2013/02/02 16:20 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
11 ≪│2018/12│≫ 01
- - - - - - 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 - - - - -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!



上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。